Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

ClinicalTrials.gov ID: NCT06635824

Public ClinicalTrials.gov record NCT06635824. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multicenter, randomized, open-label, international, Phase 3 trial to evaluate the efficacy and safety of acasunlimab in combination with pembrolizumab versus docetaxel (standard of care) in participants with locally advanced (unresectable stage IIIB/C) or programmed death ligand 1 (PD-L1)-positive metastatic non-small cell lung cancer (NSCLC) who have been treated with programmed cell death protein 1 (PD-1)/PD-L1 inhibitor and platinum-containing chemotherapy, administered either in combination or sequentially in the locally advanced (unresectable stage IIIB/C) or metastatic setting.

Study identification

NCT ID: NCT06635824
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Genmab; Industry
Enrollment: 191 participants

Conditions and interventions

Conditions

PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 25, 2024 (Actual)
Primary completion: Jul 30, 2027 (Estimated)
Completion: Sep 30, 2028 (Estimated)
Last update posted: Oct 6, 2026

2024 – 2028

United States locations

U.S. sites: 36
U.S. states: 18
U.S. cities: 31

Facility	City	State	ZIP	Site status
Arizona Blood and Cancer Specialists	Tucson	Arizona	85712	—
Usc Norris Comprehensive Cancer Center	Los Angeles	California	90089	—
Kaiser Permanente Vallejo Medical Center	Vallejo	California	94589	—
Ocala Oncology Center P.L.	Ocala	Florida	34474	—
Orlando Regional Medical Center	Orlando	Florida	32806	—
University Cancer & Blood Center, LLC	Athens	Georgia	30607	—
Piedmont Cancer Institute Atlanta	Atlanta	Georgia	30318	—
Piedmont Cancer Institute - Sandy Springs (Atlanta) Office	Atlanta	Georgia	30328	—
Piedmont Cancer Institute - Fayetteville Office	Fayetteville	Georgia	30214	—
Piedmont Cancer Institute - Newnan Office	Newnan	Georgia	30265	—
Piedmont Cancer Institute - Stockbridge Office	Stockbridge	Georgia	30281	—
Kaiser Foundation Hospitals	Honolulu	Hawaii	96817	—
University of Illinois	Chicago	Illinois	60612	—
Community Cancer Center East Medical Oncology Hematology	Indianapolis	Indiana	46219	—
Baptist Health Lexington	Lexington	Kentucky	40503	—
Norton Cancer Institute	Louisville	Kentucky	40202	—
Pikeville Medical Center	Pikeville	Kentucky	41501	—
Washington University School of Medicine	St Louis	Missouri	63110	—
St. Francis Hospital - Grand Island	Grand Island	Nebraska	68803	—
Oncology Hematology West	Omaha	Nebraska	68124	—
Oncology Hematology West, PC dba Nebraska Cancer Specialists	Omaha	Nebraska	68130	—
Stony Brook University Medical Center\|University Medical Center	Stony Brook	New York	11790	—
Novant Health Pharmacy	Charlotte	North Carolina	28204	—
Novant Health Oncology Specialists	Winston-Salem	North Carolina	27103	—
University of Pennsylvania Health System	Philadelphia	Pennsylvania	19104	—
Allegheny General Hospital	Pittsburgh	Pennsylvania	15212	—
Avera Cancer Institute	Sioux Falls	South Dakota	57105	—
Parkridge Medical Center	Chattanooga	Tennessee	37404	—
University of Tennessee Medical Center Cancer Institute	Knoxville	Tennessee	37920	—
Midtown Tennessee Oncology	Nashville	Tennessee	37203	—
Tennessee Oncology	Nashville	Tennessee	37205	—
Texas Oncology-Austin Midtown	Austin	Texas	78705	—
Texas Oncology-Austin Central	Austin	Texas	78731	—
South Austin Cancer Ctr	Austin	Texas	78745	—
University of Virginia Hematology and Oncology	Charlottesville	Virginia	22903	—
Cancer Institute At Swedish Med Ctr	Seattle	Washington	98104	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 211 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06635824, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 6, 2026 · Synced Oct 17, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06635824 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →